• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型冠状病毒肺炎诱发的细胞因子释放综合征与肺静脉血栓形成、心房心肌病及动脉内膜炎症相关

COVID-19-Induced Cytokine Release Syndrome Associated with Pulmonary Vein Thromboses, Atrial Cardiomyopathy, and Arterial Intima Inflammation.

作者信息

Goette Andreas, Patscheke Markus, Henschke Frank, Hammwöhner Matthias

机构信息

Department of Cardiology and Intensive Care Medicine, St. Vincenz Hospital, Paderborn, Germany.

Working Group: Molecular Electrophysiology, University Hospital Magdeburg, Magdeburg, Germany.

出版信息

TH Open. 2020 Sep 26;4(3):e271-e279. doi: 10.1055/s-0040-1716717. eCollection 2020 Jul.

DOI:10.1055/s-0040-1716717
PMID:32995705
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7519876/
Abstract

Coronavirus disease 2019 (COVID-19) is a viral disease induced by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), which may cause an acute respiratory distress syndrome (ARDS). First reports have shown that elevated levels of inflammatory cytokines might be involved in the development of organ dysfunction in COVID-19. Here, we can present a case of cytokine release syndrome induced by SARS-CoV-2 causing multiorgan failure and death. Of note, we can report on pulmonary vein thromboses as potential source of cerebrovascular embolic events. Furthermore, we present a specific form of an isolated inflammatory atrial cardiomyopathy encompassing atrial myocardium, perivascular matrix, as well as atrial autonomic nerve ganglia, causing atrial fibrillation, sinus node arrest, as well as atrial clot formation in the right atrial appendage. An associated acute glomerulonephritis caused acute kidney failure. Furthermore, all the described pathologies of organs and vessels were associated with increased local expression of interleukin-6 and monocyte chemoattractant protein-1 (MCP-1). This report provides new evidence about fatal pathologies and summarizes the current knowledge about organ manifestations observed in COVID-19.

摘要

2019冠状病毒病(COVID-19)是一种由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起的病毒性疾病,可能导致急性呼吸窘迫综合征(ARDS)。初步报告显示,炎症细胞因子水平升高可能与COVID-19患者器官功能障碍的发生有关。在此,我们报告一例由SARS-CoV-2引起的细胞因子释放综合征导致多器官衰竭和死亡的病例。值得注意的是,我们报告了肺静脉血栓形成可能是脑血管栓塞事件的潜在来源。此外,我们还展示了一种孤立性炎症性心房心肌病的特殊形式,其累及心房心肌、血管周围基质以及心房自主神经节,导致心房颤动、窦房结停搏以及右心耳心房血栓形成。相关的急性肾小球肾炎导致急性肾衰竭。此外,所有所描述的器官和血管病变均与白细胞介素-6和单核细胞趋化蛋白-1(MCP-1)的局部表达增加有关。本报告提供了关于致命病变的新证据,并总结了目前关于COVID-19中观察到的器官表现的知识。

相似文献

1
COVID-19-Induced Cytokine Release Syndrome Associated with Pulmonary Vein Thromboses, Atrial Cardiomyopathy, and Arterial Intima Inflammation.新型冠状病毒肺炎诱发的细胞因子释放综合征与肺静脉血栓形成、心房心肌病及动脉内膜炎症相关
TH Open. 2020 Sep 26;4(3):e271-e279. doi: 10.1055/s-0040-1716717. eCollection 2020 Jul.
2
Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab.破坏CCR5信号传导以治疗新冠病毒相关细胞因子风暴:使用leronlimab治疗的4例危重症患者病例系列
J Transl Autoimmun. 2021;4:100083. doi: 10.1016/j.jtauto.2021.100083. Epub 2021 Jan 6.
3
Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19.SARS-CoV-2 激活的肥大细胞释放组织胺,增加白细胞介素-1 水平,导致 COVID-19 中的细胞因子风暴和炎症反应。
J Biol Regul Homeost Agents. 2020;34(5):1629-1632. doi: 10.23812/20-2EDIT.
4
Specific cytokines in the inflammatory cytokine storm of patients with COVID-19-associated acute respiratory distress syndrome and extrapulmonary multiple-organ dysfunction.COVID-19 相关急性呼吸窘迫综合征和肺外多器官功能障碍患者炎症细胞因子风暴中的特定细胞因子。
Virol J. 2021 Jun 4;18(1):117. doi: 10.1186/s12985-021-01588-y.
5
Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.评估 BIO101 预防 COVID-19 肺炎患者呼吸恶化的疗效和安全性(COVA 研究):一项随机对照试验研究方案的结构化总结。
Trials. 2021 Jan 11;22(1):42. doi: 10.1186/s13063-020-04998-5.
6
IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra).白细胞介素-1(IL-1)在 COVID-19 中诱导血栓烷 A2(TxA2)的产生,导致炎症和微血栓形成:白细胞介素-1 受体拮抗剂(IL-1Ra)的抑制作用。
J Biol Regul Homeost Agents. 2020;34(5):1623-1627. doi: 10.23812/20-34-4EDIT-65.
7
Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy.新型冠状病毒-19(SARS-CoV-2)通过白细胞介素-1(IL-1)引起细胞因子风暴导致 COVID-19 的急性重症肺部炎症:一种有前途的抑制策略。
J Biol Regul Homeost Agents. 2020 Nov-Dec;34(6):1971-1975. doi: 10.23812/20-1-E.
8
Dysregulated Interferon Response and Immune Hyperactivation in Severe COVID-19: Targeting STATs as a Novel Therapeutic Strategy.严重 COVID-19 中失调的干扰素反应和免疫过度激活:靶向 STATs 作为一种新的治疗策略。
Front Immunol. 2022 May 17;13:888897. doi: 10.3389/fimmu.2022.888897. eCollection 2022.
9
Therapeutic application of estrogen for COVID-19: Attenuation of SARS-CoV-2 spike protein and IL-6 stimulated, ACE2-dependent NOX2 activation, ROS production and MCP-1 upregulation in endothelial cells.雌激素在 COVID-19 中的治疗应用:抑制 SARS-CoV-2 刺突蛋白和 IL-6 刺激、ACE2 依赖性 NOX2 激活、ROS 产生和内皮细胞中 MCP-1 的上调。
Redox Biol. 2021 Oct;46:102099. doi: 10.1016/j.redox.2021.102099. Epub 2021 Aug 17.
10
Direct Activation of Endothelial Cells by SARS-CoV-2 Nucleocapsid Protein Is Blocked by Simvastatin.辛伐他汀可阻断 SARS-CoV-2 核衣壳蛋白对血管内皮细胞的直接激活。
J Virol. 2021 Nov 9;95(23):e0139621. doi: 10.1128/JVI.01396-21. Epub 2021 Sep 22.

引用本文的文献

1
COVID-19 and Cardiac Arrhythmias: Lesson Learned and Dilemmas.新冠病毒肺炎与心律失常:经验教训与困境
J Clin Med. 2024 Nov 29;13(23):7259. doi: 10.3390/jcm13237259.
2
Cardiac Arrhythmias and Autonomic Dysfunction Associated With COVID-19: A Scientific Statement From the American Heart Association.与 COVID-19 相关的心律失常和自主神经功能障碍:美国心脏协会的科学声明。
Circulation. 2024 Nov 19;150(21):e449-e465. doi: 10.1161/CIR.0000000000001290. Epub 2024 Oct 14.
3
Pulmonary vein thrombosis: Clinical presentation and outcomes.肺静脉血栓:临床表现与结局。

本文引用的文献

1
Postmortem Examination of Patients With COVID-19.COVID-19 患者的尸检。
JAMA. 2020 Jun 23;323(24):2518-2520. doi: 10.1001/jama.2020.8907.
2
Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.干扰素 beta-1b、洛匹那韦利托那韦和利巴韦林三联治疗住院 COVID-19 患者:一项开放标签、随机、2 期试验。
Lancet. 2020 May 30;395(10238):1695-1704. doi: 10.1016/S0140-6736(20)31042-4. Epub 2020 May 10.
3
Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release Syndrome.
Thromb Res. 2024 Jul;239:109028. doi: 10.1016/j.thromres.2024.05.001. Epub 2024 May 10.
4
COVID-19 Vaccination and Cardiac Arrhythmias: A Review.COVID-19 疫苗接种与心律失常:综述。
Curr Cardiol Rep. 2023 Sep;25(9):925-940. doi: 10.1007/s11886-023-01921-7. Epub 2023 Aug 2.
5
Atrial inflammation and microvascular thrombogenicity are increased in deceased COVID-19 patients.新冠肺炎死者心房炎症和微血管血栓形成增加。
Cardiovasc Pathol. 2023 May-Jun;64:107524. doi: 10.1016/j.carpath.2023.107524. Epub 2023 Jan 14.
6
Perspective: The Case for Acute Large Vessel Ischemic Stroke in COVID-19 Originating Within Thrombosed Pulmonary Venules.观点:源于血栓形成的肺静脉的 COVID-19 导致的急性大血管闭塞性脑卒中。
Stroke. 2022 Jul;53(7):2411-2419. doi: 10.1161/STROKEAHA.121.038056. Epub 2022 May 11.
7
COVID-19 and Cardiac Arrhythmias: a Contemporary Review.新型冠状病毒肺炎与心律失常:当代综述
Curr Treat Options Cardiovasc Med. 2022;24(6):87-107. doi: 10.1007/s11936-022-00964-3. Epub 2022 Apr 19.
8
COVID-19 Vasculitis and vasculopathy-Distinct immunopathology emerging from the close juxtaposition of Type II Pneumocytes and Pulmonary Endothelial Cells.COVID-19 血管炎和血管病变-从 II 型肺泡细胞和肺内皮细胞的紧密并置中出现的独特免疫病理学。
Semin Immunopathol. 2022 May;44(3):375-390. doi: 10.1007/s00281-022-00928-6. Epub 2022 Apr 12.
9
Disturbed lipid and amino acid metabolisms in COVID-19 patients.COVID-19 患者的脂质和氨基酸代谢紊乱。
J Mol Med (Berl). 2022 Apr;100(4):555-568. doi: 10.1007/s00109-022-02177-4. Epub 2022 Jan 22.
10
Atrial Cardiomyopathy: Pathophysiology and Clinical Consequences.心房心肌病:病理生理学与临床后果。
Cells. 2021 Sep 30;10(10):2605. doi: 10.3390/cells10102605.
托珠单抗治疗重症新型冠状病毒肺炎及伴发的细胞因子释放综合征
Eur J Case Rep Intern Med. 2020 Apr 22;7(5):001675. doi: 10.12890/2020_001675. eCollection 2020.
4
COVID-19 pandemic: an overview of epidemiology, pathogenesis, diagnostics and potential vaccines and therapeutics.2019冠状病毒病大流行:流行病学、发病机制、诊断以及潜在疫苗和治疗方法概述
Ther Deliv. 2020 Apr;11(4):245-268. doi: 10.4155/tde-2020-0035. Epub 2020 May 12.
5
[Dynamic inflammatory response in a critically ill COVID-19 patient treated with corticosteroids].[接受皮质类固醇治疗的重症 COVID-19 患者的动态炎症反应]
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):220-226. doi: 10.3785/j.issn.1008-9292.2020.03.10.
6
Tocilizumab for the treatment of severe coronavirus disease 2019.托珠单抗治疗严重 2019 冠状病毒病。
J Med Virol. 2020 Oct;92(10):2042-2049. doi: 10.1002/jmv.25964. Epub 2020 May 10.
7
COVID-19 and its implications for thrombosis and anticoagulation.新型冠状病毒肺炎及其对血栓形成和抗凝的影响。
Blood. 2020 Jun 4;135(23):2033-2040. doi: 10.1182/blood.2020006000.
8
Successful Treatment of Cytokine Release Syndrome with IL-6 Blockade in a Patient Transitioning from Immune-Checkpoint to MEK/BRAF Inhibition: A Case Report and Review of Literature.免疫检查点抑制剂转换为 MEK/ BRAF 抑制剂后出现细胞因子释放综合征患者应用 IL-6 阻滞剂成功治疗:病例报告及文献复习。
Oncologist. 2020 Jul;25(7):e1120-e1123. doi: 10.1634/theoncologist.2020-0194. Epub 2020 Jun 2.
9
Endothelial cell infection and endotheliitis in COVID-19.新型冠状病毒肺炎中的内皮细胞感染与内皮炎
Lancet. 2020 May 2;395(10234):1417-1418. doi: 10.1016/S0140-6736(20)30937-5. Epub 2020 Apr 21.
10
COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome.COVID-19:一种新病毒,但熟悉的受体和细胞因子释放综合征。
Immunity. 2020 May 19;52(5):731-733. doi: 10.1016/j.immuni.2020.04.003. Epub 2020 Apr 22.